{"name":"QLT Inc.","slug":"qlt-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Visudyne for injection","genericName":"Visudyne for injection","slug":"visudyne-for-injection","indication":"Age-related macular degeneration with predominantly classic choroidal neovascularization","status":"phase_3"},{"name":"verteporfin PDT","genericName":"verteporfin PDT","slug":"verteporfin-pdt","indication":"Age-related macular degeneration with predominantly classic choroidal neovascularization","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"QLT091001","genericName":"QLT091001","slug":"qlt091001","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Visudyne for injection","genericName":"Visudyne for injection","slug":"visudyne-for-injection","phase":"phase_3","mechanism":"Visudyne (verteporfin) is a photosensitizing agent that accumulates in abnormal blood vessels and is activated by light to produce reactive oxygen species that destroy those vessels.","indications":["Age-related macular degeneration with predominantly classic choroidal neovascularization","Pathologic myopia with choroidal neovascularization","Polypoidal choroidal vasculopathy"],"catalyst":""},{"name":"QLT091001","genericName":"QLT091001","slug":"qlt091001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"verteporfin PDT","genericName":"verteporfin PDT","slug":"verteporfin-pdt","phase":"marketed","mechanism":"Verteporfin is a photosensitizing agent that accumulates in abnormal blood vessels and is activated by light to generate reactive oxygen species that destroy those vessels.","indications":["Age-related macular degeneration with predominantly classic choroidal neovascularization","Pathologic myopia with subfoveal choroidal neovascularization","Polypoidal choroidal vasculopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOWV9QTlIxR0V4Z1hBbGlDUVZEWG5hb1NYRzFwWmVlZlA1S0lMR0h0akFrVGlKZy1NWnozc3gtdGg2Vm44TDNTejlKdWVOLVY2OWlEdkZEZmUtVmVBRk9mSkhwY1BVYlZMcVAycmdIUS1ldUVhSFN6M0NWWWw1LWhVSVpjbGltZHowWjQ5a0p5YjNscGllcDYtM0ViTk1tZmZGYjJZdDFSaWJXN1Vrb0IxOHpvMU5nVHJOZ19rTlVQUVFQTFpDS1Fj?oc=5","date":"2024-07-23","type":"regulatory","source":"The New York Academy of Sciences","summary":"Equivalence of Complex Drug Products: Scientific and Regulatory Challenges - The New York Academy of Sciences","headline":"Equivalence of Complex Drug Products: Scientific and Regulatory Challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNcnpuTEVyRElmMjlwcll2QWdGVXlvdi1tOERraEJjWjM3Y3F4YkJnbUxnREZneGxpSUVBZHZWdjE2T1V2cnN3aDdyYjg4NzNubEZsZnRVbTRXQVVMYnlqNVVCMVNmU1QzT0JfdkJzaW9WRjRTOXl0VkIxeTRzWk9RR2hLenRCYXBjNmQwazZPWlIzdVBNQTlzOEZFa0Y1QUFkc3Bn?oc=5","date":"2024-03-09","type":"pipeline","source":"The Globe and Mail","summary":"B.C. biotech boom: Vancouver looks to join the global big leagues of modern medicine - The Globe and Mail","headline":"B.C. biotech boom: Vancouver looks to join the global big leagues of modern medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNbU8xWVdianc1djVkd2dWMTRPempBZ3FCMVU5SDN0T05yS0ZNWHhPbmxiMUtYMVpEZ2F2X2IyZ2Z5Y004Q1VmQmVrTjJzUzZkM1oxTlVwREJHelMyaExPNmk0ZHkzS1lrc2l0eXdkdDZPNDAxNkxPUV9tRHdvQi1nR1Z3dS1yQQ?oc=5","date":"2023-03-17","type":"pipeline","source":"Dermatology Times","summary":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal - Dermatology Times","headline":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5fdjFtbW9lQy13LVpCSWJsRWwtWXkxbk1vWDJRWmhtZGE4WGNlMGwwN1pnektBXzJ0QlJZSUo0MnBldGxhVHBZeVROSmdES1pqeUVCOWRNSHRsQU0yRW9vOU5laFNKeXlDdU9sNQ?oc=5","date":"2022-01-11","type":"pipeline","source":"Pharma Voice","summary":"Talent Pool - Pharma Voice","headline":"Talent Pool","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPNkltNHlhdEhzVFY2cnNwcy1wTGFtd2JuaGttZG52UFBhT0NLa21ES2c2dWUxeE55SDlkUUx4YXYwVlBJWFViZUcwOEdXSHVvT1owRUcyc2ZNVmYxYlRqZ285UXRwak1ZYkJvMnVVdnVncU8yb29NVUFJLVV0SHo5Vlo1OWo3dmY3OU5tVE9sd2VCNW1SZWtIRXRfTm1aakFDMXJKN0p1WmJEV2JxWS1TeDBBU3dWc3V6UDJVbjIxWFp1UXpxU2JJcEJBV29sOGtmeERGLVM5SnI4OHdUVjVtU29LY3N5d2prY2x6aDNJejRaa0J6MHlEY0M5bXVwWWhvSzFwdEhhOEpYejNuT04yZFVDbU9Zem1GLUFv?oc=5","date":"2016-11-29","type":"deal","source":"GlobeNewswire","summary":"Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger - GlobeNewswire","headline":"Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOSS1acFRycUw5b29lNzY2YVkwdnhBTHZZQkN5a29UVDVTWDZ0c0s5Q2dKOGlfX2xlYmhkWEJlaW9lRm1lVTFMc0ZpcHZiZDI4cU9JLUJwN1hXekJuTG9OTW1XZVVEZ05FMW03MGd4ZjUxb2k1LTZNb3k1QzhjX19oSzc4ODZ2alpoMXNuOS11MVFocTNEUlliZ1pjTV9ZYTFWSHFURm5GM04tMHlqalVLVjlmQmphQnM?oc=5","date":"2016-06-15","type":"pipeline","source":"BioPharma Dive","summary":"Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT - BioPharma Dive","headline":"Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQOGpPTl9wUDFIYWFVWUNwcEN2QlVWV2p5SmtUWkV4RTI5NEgxSEF5X3JteXdEQWNEMWJhZHFOWi1oZnBOZ2lfOVRRZ2dzVTJWQVBkTGlLYU1mWmZaVWJaTE5kRzQ4UmNTQjdLRmNSSldubWxtbHV3dElfU0UxcXVDdkpTTGVaekZadmNPSjN3WEN2WnJpa0FvM0dIdWVUNnlrYmVMR1huUEFBY3hEUWtQUEFnUjR5R1FQazlmdkZVN3p4Nm5ZaU90UzFSMk92ZXNFeGow?oc=5","date":"2016-06-15","type":"deal","source":"GlobeNewswire","summary":"Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger - GlobeNewswire","headline":"Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPbVkyZzNDZWE1d1VCMWtqb1Q3OHdkd2oydk0wUTZCWUNiT3BvOUJHc0dHYkpaclR0Rkd2Z3VRaU1WY0xpQXFtMnpyXzBSZkxBQV9Jbnhmc0pyWXZ3eVp1VE1IaW40ODlPbkg3U1hHbF82MzhoZWFQOEZLNTVIenppQkJ0eXZleDBKUGNIY1BmRjE3S1NwT2ZFN1ktMy13Zw?oc=5","date":"2015-06-10","type":"deal","source":"Contract Pharma","summary":"POZEN Acquires Tribute Pharmaceuticals in $146M Deal - Contract Pharma","headline":"POZEN Acquires Tribute Pharmaceuticals in $146M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPSWVnY0FKdTR5bVhYMnRwNjdTdGtwT1dUbDdzLW11emptTjFFZ0VSUDNjalNfc1FWaGkyS3l1dkhFWDdsT1ZuX0NuTkRUcGxfUWRteHo1M29GMGtmNFREY3FJVURtMkZqSEJHWkhjODBEXzlBYllROUREUmZTM0FPSmQtMzdRbmF4ZTY0cmVtUlY0UQ?oc=5","date":"2014-10-22","type":"pipeline","source":"The University of Rhode Island","summary":"URI to present Distinguished Achievement Awards, Oct. 25 – Rhody Today - The University of Rhode Island","headline":"URI to present Distinguished Achievement Awards, Oct. 25 – Rhody Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOa3l2R1dEWFUwZFhXeG16RXduNTRoMTM0NC10Q0NDRDNiRXF2VFFRNDN3M19ISzFMNXFrUUtKZU5vOWkyYTAwckdqLVVsLVh2VDl1NGpGeVBRZEo2eXg0ai1KR2dOZUNkSmlMZVNneFBpX3pRV0hwUHFCNFdreHpPaUdvNENJazRSZzNHWmwtZkp4OUxnYXFSSjdB?oc=5","date":"2014-06-25","type":"deal","source":"Business in Vancouver","summary":"U.S. pharma firm Auxilium buys out Vancouver’s troubled QLT in $300-million deal - Business in Vancouver","headline":"U.S. pharma firm Auxilium buys out Vancouver’s troubled QLT in $300-million deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPc2h4Z0NFRFlMUTR2LUJlSnlPYUJmZVpibEhlWGRwNjBFdkVDQVNnWDZRM1N1RFM5RlhzZHRobjlOWTlSN05KUGxMMXdma3pfTlVaSG5IbFZvX1dkZlluWDVCeVNpRXJYbF9MQXFsWVFSSUF3U3ZuREI3RmJOZUZ4QQ?oc=5","date":"2012-07-09","type":"pipeline","source":"CBC","summary":"QLT cuts workforce by two thirds - CBC","headline":"QLT cuts workforce by two thirds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1iRmk0dUt4eHEwdnpXWWlfUGU5SWJIeGxwRkdyOGlpMEhEN0UxMHpHU213TFpSN2ZPYmJ6X3VEcVB2QnpTMEZvd2ljdk1fcFB2Tlo2aFNMZk96YXZodHJnQkJyYWcwYnU1VDlMYmM1LTVodWZqT0E?oc=5","date":"2008-09-03","type":"pipeline","source":"BCBusiness","summary":"QLT Inc: A Place Called Hope - BCBusiness","headline":"QLT Inc: A Place Called Hope","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":1,"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}